DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities
Updated: Mar 14
FOR IMMEDIATE RELEASE Contact: DEA Public Affairs (571) 776-2508
DEA extends many telemedicine flexibilities adopted during the COVID-19 PHE with appropriate safeguards
WASHINGTON - Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 public health emergency. The public will be able to comment for 30 days on the proposed rules.
For more information, visit: https://www.dea.gov/press-releases/2023/02/24/dea-announces-proposed-rules-permanent-telemedicine-flexibilities